Taysha Gene Therapies, Inc. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Taysha Gene Therapies, Inc. (TSHA) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $23.60 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-03-19
- Taysha Gene Therapies, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for the quarter ending 2019-12-31 was $200.00K.
- Taysha Gene Therapies, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $23.60M, a 6.79% increase from fiscal 2024.
- Taysha Gene Therapies, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $22.10M.
- Taysha Gene Therapies, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was -$9.00M, a 121.03% decline from fiscal 2022.
- Taysha Gene Therapies, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $42.80M, a 11.57% decline from fiscal 2021.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 3 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|---|
| 2025-12-31 | $23.60M 10-K · filed 2026-03-19 | |
| 2024-12-31 | $22.10M 10-K · filed 2026-03-19 | |
| 2023-12-31 | -$9.00M 10-K · filed 2025-02-26 | |
| 2022-12-31 | $42.80M 10-K · filed 2024-03-19 | |
| 2021-12-31 | $48.40M 10-K · filed 2023-03-28 | |
| 2020-12-31 | $9.50M 10-K · filed 2022-03-31 | |
| 2019-12-31 | $200.00K 10-K · filed 2021-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |